Xylo Bio: A Revolutionary Shift in Neurotherapeutics and Leadership Strategy

Transforming Neurotherapeutics: Xylo Bio's Rebranding

In a significant strategic move, Psylo has officially rebranded as Xylo Bio, reflecting its enhanced commitment to pioneering neurotherapeutic solutions aimed at addressing psychiatric and neurological disorders. This change not only signifies a new name but also embodies a renewed focus on innovative approaches in treating complex conditions.

The rebranding comes on the heels of Psylo's impressive advancements in its drug discovery platform, which integrates computational enhancements to drive the design and optimization of neuroplastogens—a groundbreaking class of therapies capable of stimulating the growth and remodeling of neural circuits. These therapies aim to address the root causes of neurological dysfunctions rather than merely alleviating symptoms.

Key Developments: The Introduction of XYL-1001

Central to Xylo's mission is its lead candidate, XYL-1001. This innovative drug is crafted to 'rewire' neural connections without inducing hallucinatory side effects, representing a new frontier in neurotherapeutics. The company has initiated the scale-up of XYL-1001's manufacturing in preparation for first-in-human clinical trials slated for mid-2026. This highlights Xylo's commitment to advancing its drug pipeline while establishing a strategic foothold in the biopharmaceutical landscape.

Joshua Ismin, the CEO of Xylo, emphasized the significance of this transformation: "Our rebranding reflects more than a name change; it signifies our renewed commitment to advancing neurotherapeutics with precision, innovation, and a patient-centered focus." He also expressed excitement about collaborating with partners who share the vision of using targeted neurotherapeutics to transform patients' lives.

Expanding the Leadership Team

Building on the momentum of its Series Seed funding—which included contributions from prominent investors like Tenmile and Main Sequence Ventures—Xylo has further solidified its leadership. The appointments of Dr. Elaine Stead, a notable venture partner, and Margarita Chavez, a veteran in biotech investments, are set to enhance the company's operational strategy and vision. Both board members have voiced their enthusiasm for Xylo's potential in delivering innovative solutions for patients facing psychiatric and neurological challenges.

Dr. Stead remarked, "Xylo Bio is primed to deliver transformative therapies to meet the urgent needs of patients with neural disorders. I am thrilled to participate in the company's evolution." Similarly, Chavez highlighted the innovative drug design processes at Xylo, asserting her pride in working alongside a team of exceptional talent committed to making impactful changes in neurotherapeutics.

Active Engagement at the JPM Healthcare Conference

Xylo's journey towards redefining neurotherapeutics is now drawing significant attention, particularly at industry events such as the JPM Healthcare Conference. This unique platform allows Xylo to discuss emerging opportunities for collaboration and innovation to broaden their reach and further establish their brand identity within the sector.

About Xylo Bio

Founded in 2021 as Psylo and rebranded in 2025, Xylo Bio dedicates itself to developing targeted neurotherapeutics through advanced computational and neuroscience methodologies. Its focus on neuroplastogens aims to not only restore but enhance brain function for those battling various psychiatric and neurological disorders. As Xylo moves forward, the company's mission remains clear: to revolutionize how neurotherapeutics are conceptualized, designed, and delivered.

For more information about Xylo Bio's innovative work, visit www.xylo.bio.

As this vibrant company charts its course through the biopharma landscape, the promise of pioneering therapies lies on the horizon, ready to address critical unmet needs in mental health.